WA
RXII

Waverly Advisors’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Waverly Advisors’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-2
Closed – – 896
2013
Q4 		$0 Hold
2
– – ﹤0.01% 872
2013
Q3 		$0 Buy
+2
New – ﹤0.01% 582

Other funds holding RXII

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Waverly Advisors's RXII Position: Q1 2014 in Review

Waverly Advisors sold out of GALENA BIOPHARMA INC COM (RXII) in Q1 2014, closing a stake of 2 shares.

Waverly Advisors first reported a position in RXII in Q3 2013 and held it in 2 quarters. The position peaked at $0 in Q4 2013. 88 funds tracked by Wall St. Rank hold RXII as of Q1 2014.

  • Waverly Advisors reported no remaining GALENA BIOPHARMA INC COM position as of Q1 2014 after selling out during the quarter.
  • Waverly Advisors sold 2 GALENA BIOPHARMA INC COM shares in Q1 2014.
  • Waverly Advisors first reported a position in GALENA BIOPHARMA INC COM in Q3 2013 and held it in 2 quarters.
  • Waverly Advisors's GALENA BIOPHARMA INC COM position peaked at $0 in Q4 2013.
  • 88 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q1 2014.

Based on Waverly Advisors's 13F filing for Q1 2014, filed 28 Apr 2014.